| abstract |
The present invention provides a SARS-CoV-2 protein-derived epitope peptide that has an ability to induce cytotoxic T cells. The present invention also provides a polynucleotide encoding the peptide, an antigen-presenting cell presenting the peptide, a cytotoxic T cell (CTL) targeting the peptide, and a method of inducing the antigen-presenting cell or the CTL. The present invention further provides a composition and a pharmaceutical composition comprising the same as an active ingredient. Furthermore, the present invention provides a method of treating and/or preventing the coronavirus disease and/or reducing the severity of the disease using the peptide, the polynucleotide, the antigen-presenting cell, the cytotoxic T cell or the pharmaceutical composition according to the present invention. Also provided is a method of inducing an immune response to the coronavirus infection. Also provided is a method of checking the history of the coronavirus infection by detecting a TCR sequence in a target. |